LataMed AI Corp. (OTC: LMED) announced that it expects to formally submit a corporate action request to FINRA today seeking approval of a proposed five-for-one forward stock split, along with proportional increases in authorized common and preferred stock. The move is intended to support the company's broader long-term operational scalability, strategic flexibility, capitalization planning, and future growth initiatives as it advances telehealth infrastructure deployment and healthcare analytics integration in Latin America and other emerging markets.
The proposed corporate action would apply proportionally to all issued and outstanding shares of common stock and outstanding preferred stock designations, including Series C Voting Preferred Stock. The company emphasized that the split does not involve debt restructuring, recapitalization, or reduction in shareholder ownership percentages. No fractional shares are expected; any fractional interests would be rounded up to the nearest whole share.
Management stated that the forward stock split is part of a broader effort to align its capital structure with its ongoing transition into digital healthcare infrastructure and AI-driven telehealth operations. Dr. Kevin Rodan Levy, CEO, said, “As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform.”
The company recently commenced initial operational activities for its telehealth platform in Venezuela after receiving regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). This milestone marks a key step in LataMed's expansion strategy in emerging markets.
The proposed forward stock split remains subject to FINRA review and approval, completion of applicable regulatory processing, and final corporate implementation procedures. No assurance can be provided regarding the timing or ultimate effectiveness of the proposed action. Investors are cautioned that the company is a development-stage enterprise and has not generated revenues from its current business operations.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.